Government to compare vaccines Covaxin, Covishield on different parameters

The Ministry of Health and Family Welfare said on Thursday that the government will compare the coronavirus vaccines - Covishield and Covaxin on different parameters for recordkeeping purposes

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Covaxin coronavirus vaccine
ANI General News
1 min read Last Updated : Jan 15 2021 | 8:31 AM IST

The Ministry of Health and Family Welfare (MoHFW) said on Thursday that the government will compare the coronavirus vaccines - Covishield and Covaxin on different parameters for recordkeeping purposes.

According to the Union Health Ministry, the comparison parameters will include vaccine platform, physical specifications, dosage, cold chain storage requirements, and minor adverse events following the immunisation.

"Comparative factsheet for Covid-19 vaccines (Covishield and Covaxin) has been prepared for recordkeeping purposes. Comparison parameters will include vaccine platform, physical specifications, dosage, cold chain storage requirements, and minor adverse events following immunisation," said the MoHFW.

India has given emergency use authorisation to two COVID-19 vaccines Covishield and Covaxin, both being manufactured in the country.

While Covishield has been developed by AstraZeneca and Oxford University, Covaxin is an indigenous vaccine developed by Bharat Biotech in collaboration with ICMR.

Around three lakh healthcare workers will be inoculated at 2,934 sites across the country on the first day of the massive nationwide Covid-19 vaccination drive which is set to begin from January 16, the health ministry said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Serum Institute of IndiaBharat BiotechCoronavirus VaccineHealth Ministry

First Published: Jan 15 2021 | 8:15 AM IST

Next Story